Aoxiang Pharma
奥翔药业
Executive Summary
Aoxiang Pharma is a Zhejiang-based CDMO with solid financial performance (¥690M revenue, ¥229M net profit in Q3 2024) focused on generic drug development and manufacturing. The company recently achieved regulatory milestones with entecavir tablets and tofacitinib citrate tablets receiving approvals, indicating active pipeline execution. Under congressional pressure regarding BIOSECURE Act compliance, creating moderate partnership risk for US pharma companies. Recent share buyback and high-tech enterprise recertification suggest financial stability and R&D investment focus.
Structure: Public company listed on Shanghai Stock Exchange (603229.SS) with at least one wholly-owned subsidiary handling drug registrations. Limited visibility into full corporate structure, but recent announcements reference fundraising activities and subsidiary operations typical of Chinese pharmaceutical companies. Standard due diligence should examine potential VIE structures and subsidiary relationships not disclosed in available data.
Latest Financials
Revenue: 690126439.62, Net Profit: 228985673.66. Source: East Money (603229)
Period: 2024-09-30 | Source: eastmoney
Corporate Events
奥翔药业：奥翔药业关于全资子公司获得恩替卡韦片《药品注册证书》的公告
CNINFO announcement for Aoxiang Pharma (603229.SS)
奥翔药业：奥翔药业关于提前归还部分用于临时补充流动资金的募集资金的公告
CNINFO announcement for Aoxiang Pharma (603229.SS)
奥翔药业：奥翔药业关于公司通过高新技术企业重新认定的公告
CNINFO announcement for Aoxiang Pharma (603229.SS)
奥翔药业：奥翔药业关于合作产品枸橼酸托法替布片获得境外上市许可的公告
CNINFO announcement for Aoxiang Pharma (603229.SS)
奥翔药业：奥翔药业关于股份回购实施结果暨股份变动的公告
CNINFO announcement for Aoxiang Pharma (603229.SS)
Aoxiang Pharma Financial Report
Revenue: 690126439.62, Net Profit: 228985673.66. Source: East Money (603229)
BIOSECURE Risk
Company is under congressional pressure but not yet designated under BIOSECURE Act, creating regulatory uncertainty but not immediate prohibition
Key Exposures:
- •Congressional scrutiny of Chinese CDMO relationships
- •Potential future BIOSECURE designation
- •Supply chain restrictions for US government contracts
Mitigation: No visible mitigation efforts or statements addressing BIOSECURE compliance in available data
BD Intelligence
Therapeutic Areas:
Recent Deals: Collaborative product tofacitinib citrate tablets received overseas marketing authorization, indicating active international partnerships
Approach: Approach with caution given BIOSECURE risks; focus on non-government contract opportunities and maintain regulatory compliance monitoring
Red Flags
- ⚠Congressional pressure under BIOSECURE Act
- ⚠Limited transparency on corporate structure and key personnel
- ⚠Potential supply chain restrictions for US government-related business
- ⚠Generic drug focus may limit differentiation and pricing power
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.